Considering that the NOTCH inhibitor has an off-target effect and is toxic if applied systemically, designing a more effective way to target TGF-β1 can be a feasible immunomodulatory intervention for DLBCL treatment. The gene discussed is TGFB1; the disease is diffuse large B-cell lymphoma.